Oxaliplatin Injection · 198 days since initial FDA posting
Brand: OXALIPLATIN
FDA lists Oxaliplatin Injection as To Be Discontinued (Fresenius Kabi USA, LLC).
No availability text on this FDA row.
Oxaliplatin Injection: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Oxaliplatin Injection
- Manufacturer
- Fresenius Kabi USA, LLC
- Dosage Form
- Injection
- Presentation
- Oxaliplatin, Injection, 5 mg/mL (NDC 63323-750-10)
- Package NDC
- 63323-750-10
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Feb 25, 2026
- Last Updated
- Feb 25, 2026
- Therapeutic Category
- Oncology
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
A business decision was made to discontinue manufacture of the drug.
Nearby, Other Oxaliplatin Shortage Records
Oxaliplatin Injection
Sandoz Inc.
Injection
Oxaliplatin Injection
Sandoz Inc.
Injection
Oxaliplatin Injection
Novast Labs
Injection
Oxaliplatin Injection
Novast Labs
Injection
Oxaliplatin Injection
Fresenius Kabi USA, LLC
Injection
FDA reason on file: A business decision was made to discontinue manufacture of the drug. General shortage guidance lives on the tracker hub.